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Abstract 
Background: The transcriptional repressor promyelocytic leukemia zinc finger protein (PLZF) is critical for the regula‑
tion of normal stem cells maintenance by establishing specific epigenetic landscape. We have previously shown that 
CBP/p300 acetyltransferase induces PLZF acetylation in order to increase its deoxynucleotidic acid (DNA) binding 
activity and to enhance its epigenetic function (repression of PLZF target genes). However, how PLZF is inactivated is 
not yet understood.
Results: In this study, we demonstrate that PLZF is deacetylated by both histone deacetylase 3 and the NAD+ 
dependent deacetylase silent mating type information regulation 2 homolog 1 (SIRT1). Unlike other PLZF‑interacting 
deacetylases, these two proteins interact with the zinc finger domain of PLZF, where the activating CBP/p300 acetyla‑
tion site was previously described, inducing deacetylation of lysines 647/650/653. Overexpression of histone dea‑
cetylase 3 (HDAC3) and SIRT1 is associated with loss of PLZF DNA binding activity and decreases PLZF transcriptional 
repression. As a result, the chromatin status of the promoters of PLZF target genes, involved in oncogenesis, shift from 
a heterochromatin to an open euchromatin environment leading to gene expression even in the presence of PLZF.
Conclusions: Consequently, SIRT1 and HDAC3 mediated‑PLZF deacetylation provides for rapid control and fine‑tun‑
ing of PLZF activity through post‑transcriptional modification to regulate gene expression and cellular homeostasis.
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Background
Promyelocytic leukemia zinc finger protein (PLZF, 
ZBTB16), a transcription factor containing a bric à brac-
tramtrack-broad complex (BTB) multimerization/repres-
sion domain and 9 zinc finger (ZF) motifs, belongs to a 
large family of transcriptional repressor proteins [1, 2]. 
First identified as a fusion partner of retinoic acid recep-
tor alpha (RAR) in acute promyelocytic leukemia (APL) 
in cases with a t(11; 17) translocation [3], PLZF is now 
generally described as a transcriptional repressor and, 
more precisely, an epigenetic regulator. The biological 
activity of PLZF include its ability to regulate hematopoi-
etic stem cell quiescence [4–6], maintain spermatogen-
esis [6–8] and induce the formation of specialized natural 
killer T cells (NKT) [9, 10]. Both direct and indirect PLZF 
functions have been elucidated and range from control 
of retrotransposon levels and mobility, to angiogenesis 
and cell signaling [6, 11, 12]. Loss of normal PLZF func-
tion in myeloid cells bearing the t(11; 17) is part of the 
oncogenic mechanism in acute promyelocytic leukemia 
development [13–15] while loss of expression of PLZF 
in melanoma [16], and a wide variety of solid tumors, 
including breast, prostate and glioblastoma (http://www.
oncomine.org), suggest that PLZF may be a bona fide 
tumor suppressor.
Like a growing number of transcription factors such 
as p53 [17] and the related BTB/ZF factor Bcl-6 [18], 
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the PLZF protein is regulated by acetylation of lysine 
residues. Unlike BCL6, where acetylation is associated 
with degradation of the Bcl-6 protein, and loss of BCL6 
repression, acetylation of PLZF enhances DNA binding 
and subsequent repression of gene expression by PLZF 
[19]. We previously showed that CBP/p300 is the acetyl-
transferase protein that binds to PLZF, and acetylates 
several lysine residues in the zinc finger DNA binding 
domain. Loss of PLZF acetylation blocks PLZF repres-
sor function and leads to global and specific hypometh-
ylation of the mouse genome as well as impairment of 
hematopoietic and germinal stem cells maintenance [6]. 
While interaction with CBP/p300 triggers PLZF activa-
tion, the counterpart PLZF deacetylation and thus its 
inhibition mechanisms are still unknown.
A dynamic interplay between acetylation and deacety-
lation has been described [20]. The reciprocal deacetyla-
tion of proteins is carried out by the histone deacetylase 
enzyme family (HDAC) now referred to as protein dea-
cetylases [21]. Not surprisingly, acetylation/deacetylation 
mechanisms are disrupted in cancer [22–24] and can 
modulate cell proliferation and cellular immunity [25]. 
The HDAC enzymes are divided into three classes. The 
class I consist of nuclear HDACs, which together with 
class II HDACs, shuttle between cytoplasm and nucleus. 
They share sequence similarity, are Zn2+ dependent dea-
cetylases and regulate histone and non-histone protein 
functions [21]. The class III HDACs are sirtuins, NAD+ 
dependent deacetylases (SIRT 1–7), structurally unre-
lated to the classical HDAC I and II families [26–28]. 
Silent mating type information regulation 2 homolog 
1 (SIRT1), a member of the sirtuin family, deacetylates 
non-histone proteins including transcription factors like 
p53, c-myc (reviewed in [29, 30]). Sirtuins have complex 
functions but are centrally involved in monitoring cellu-
lar metabolism and redox status, particularly in ageing 
[28, 31, 32]. SIRT1 is consistently over-expressed in acute 
myeloid leukemia [33, 34] while its expression is low in 
human and mouse bone marrow progenitor cells [35]. 
Interaction of PLZF with classes I and II HDACs, includ-
ing HDAC1, 2, 4, 5, 6 and 9, to PLZF bound chromatin 
complex mediates PLZF’s epigenetic suppressor func-
tion [13, 36–39]. The BTB multimerization/repression 
domain of PLZF is in part accountable for the recruit-
ment of co-repressor complexes including deacetylase 
proteins [13, 39], while the zinc finger motifs of PLZF 
tether these protein complexes to specific genetic tar-
gets. Curiously, HDAC3 is the only member of the class 
I family, that is neither recruited on DNA by nor asso-
ciated with PLZF repression [6]. However, recent studies 
have shown that PLZF can directly interact with HDAC3 
in order to form a corepressor complex interacting with 
NF-kB at the promoters of early inflammatory response 
genes [40, 41]. Furthermore, the nuclear-localized SIRT1 
is not associated with PLZF repressor function but nev-
ertheless binds to a fragment of the zinc finger domain 
of PLZF similar to that we had previously described for 
the RING finger protein promyelocytic leukemia protein 
(PML) ([42] and data not shown).
In this work we describe PLZF as a new substrate for 
HDAC3 and SIRT1 proteins. These interactions induce 
PLZF deacetylation resulting in subsequent loss of PLZF 
cellular localization, DNA binding and epigenetic func-
tion. These data identify the mechanisms controlling 
the acetylation/deacetylation cycle of the transcriptional 
activity of PLZF offering the possibility of fine tuning for 
its activity.
Results
SIRT1 and HDAC3 interact with PLZF zinc finger domain 
leading to its deacetylation
It is well established that PLZF can interact with HDAC 
protein members through its BTB domain in order to 
mediated histone deacetylation at target genes. How-
ever, we have shown that HDAC3 and SIRT1 could also 
interact with PLZF ([13] and data not shown) suggest-
ing that these specific interactions might serve a purpose 
other than to contribute to PLZF-mediated repres-
sion. An in  vivo interaction between PLZF and SIRT1 
(Fig.  1a.1) and between PLZF and HDAC3 (Fig.  1a.2) 
was observed by immunoprecipitation of endogenous 
proteins in human myeloid cells, KG1a. To character-
ize the domain within PLZF interacting with HDAC3 
and SIRT1 in  vitro interaction assays were performed. 
GST pull-down experiments confirmed that the full-
length GST-PLZF protein could interact with His-SIRT1 
and in  vitro translated HDAC3 proteins (Fig.  1b). More 
detailed mapping of this interaction demonstrated that 
SIRT1 and HDAC3 do not interact with the BTB domain 
(Fig. 1b.1) but have a specific affinity for the C-terminal 
PLZF zinc fingers 3–9 (Fig.  1b.2, b.3, lower panel), the 
domain of PLZF previously shown to be acetylated by 
CBP/p300 on lysine residues located in zinc fingers 6 and 
9 (ZF6 and ZF9) [19]. Indeed, CBP/p300-induced PLZF 
acetylation at its zinc finger 9 (ZF9) is a prerequisite for 
its repressor function [19] and its deacetylation is thus 
necessary to modulate its cellular activity [6]. To test the 
activity of these two deacetylase candidates, SIRT1 and 
HDAC3, 293T cells were transfected with FLAG-tagged 
PLZF, CBP/p300 acetyltransferase, HDAC3 and SIRT1 
expression vectors. After PLZF immunoprecipitation 
and immunoblotting with an anti-acetyl-lysine antibody 
(α-AcK) to detect only the acetylated PLZF protein, we 
first confirmed that expression of CBP/p300 increases the 
amount of acetylated-PLZF as previously described [19] 
(Fig. 2a). Expression of either wild-type SIRT1 (Fig. 2a.1) 
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Fig. 1 PLZF interacts with SIRT1 and HDAC3. Cellular coimmunoprecipitation of PLZF with deacetylases (a). Endogenous coimmunoprecipitation 
of PLZF and SIRT1 (a.1). Antibodies to PLZF and SIRT1 were used to precipitate each protein from 2 × 107 KG1a cells as noted, and precipitates 
immunoblotted for PLZF (top panel) or SIRT1 (bottom panel) independently. Endogenous coimmunoprecipitations of PLZF and HDAC3 (a.2). Whole‑
cell extracts from KG1 cells were subjected to immunoprecipitation with anti‑HDAC3 (HDAC3 IP) and anti‑PLZF (PLZF IP) antibodies followed by 
immunoblotting with monoclonal antibodies raised against HDAC3 antibody (αHDAC3) and PLZF (αPLZF). In vitro mapping of PLZF interaction 
domains (b). Direct in vitro interaction between PLZF and SIRT1, and PLZF and HDAC3 was mapped by GST affinity chromatography using full 
length GST‑PLZF. b.1 Both SIRT1 and HDAC3 don’t interact with the N‑terminus repressor domain of PLZF (GST‑BTB/POZ). b.2 Top panel bacterially 
expressed His‑tagged SIRT1 was incubated with bacterially expressed GST, or GST‑PLZF, subjected to electrophoretic separation and immunoblot‑
ted with an antibody against the HIS epitope tag. GST1–5, PLZF zinc fingers 1–5 only; GST‑PLZF, full‑length PLZF; GST3–9, zinc fingers 3–9 only; 
GST1–9, zinc fingers 1–9 only. Input, 5 % of volume of SIRT1 sample used in each pull‑down. Lower panel ponceau staining of the blot, indicating 
amount of each protein loaded. Asterisks indicate the GST‑fusion species in each lane. b.3 Direct in vitro interaction was mapped by GST or in vitro 
immunoprecipitation using GST, GST‑PLZF or 35S‑labeled PLZF translated using the rabbit reticulocyte system (35S‑PLZF) and incubated with 
35S‑labeled HDAC1 (35S‑HDAC1) and HDAC3 (35S‑HDAC3). Bottom panel GST pull‑down using the GST3–9, zinc fingers 3–9; GST1–9, zinc fingers 1–9; 
GST‑PLZF, full length PLZF and GST only. Anti‑PLZF antibody (αPLZF) was used for coimmunoprecipitation to evaluate interactions between the 
PLZF, HDAC1 and HDAC3 proteins
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or HDAC3 (Fig.  2a.2) reduced the quantity of acety-
lated PLZF, suggesting that PLZF could be a substrate 
of HDAC3 and SIRT1 deacetylases. In order to quantify 
the levels of PLZF acetylation in presence of these spe-
cific deacetylases, cell extracts were also subjected to a 
nanofluidic proteomic immunoassay in order to visualize 
the levels of PLZF acetylated isoforms. As shown in the 
electropherograms of Fig. 2b, the PLZF antibody detects 
both acetylated and non-acetylated PLZF isoforms. The 
presence of HDAC3, and in a lesser extent SIRT1, is asso-
ciated with a decrease of detection of PLZF acetylation 
forms associated with an increased detection of the non-
modified PLZF isoform (Fig. 2b, c). 
HDAC3 and SIRT1 antagonize PLZF DNA binding 
and transcriptional activities
We previously showed that the PLZF protein has an 
increased affinity to DNA when acetylated and that 
mutation of PLZF lysines 647/650/653 to glutamine 
residues (PLZF-Q) mimics PLZF acetylation and binds 
constitutively to PLZF DNA targets [6, 19]. There-
fore, we examined the ability of PLZF to bind to DNA 
in complementary in  vitro assays in the presence of 
SIRT1 and HDAC3 deacetylases. Firstly, in a lucif-
erase reporter assay the presence of HDAC3 partially 
blocked wild type PLZF-mediated repression (from 60 
to 20 % repression activity) and not the PLZF-Q mutant 
(Fig.  3a.1), while expression of HDAC3 on its own had 
no effect on the reporter gene. Chromatin immunopre-
cipitation (ChIP) assays were employed to determine 
whether HDAC3 reduction of repression by PLZF was 
reflected by decreases in the occupancy of PLZF bind-
ing site. The result of this analysis shows a loss of wild 
type PLZF DNA binding activity, and not the PLZF-Q 
mutant, on the reporter plasmid when HDAC3 was co-
expressed and, addition of HDAC3 inhibitor, Trichostatin 
A (TSA), restore PLZF ability to bound DNA (Fig. 3a.2). 
As shown above, treatment with the HDAC3 inhibitor 
TSA restored the capacity of PLZF to bind DNA but did 
not restore the ability of PLZF to repress the reporter 
gene (Fig.  3a.1, a.2 respectively). The latter finding may 
possibly be due to the concomitant inhibition by TSA of 
class I HDACs needed for PLZF-mediated repression. 
Finally, we used a chimeric PLZF, containing the nine 
zinc finger of PLZF fused to the VP16 activating domain, 
replacing the repression domain of the wild-type protein 
(9znfPLZF-VP16) [43]. This protein activates a PLZF bind-
ing site-containing reporter. Co-expression of increasing 
amounts of HDAC3 significantly decreases the activa-
tion of the reporter, likely due to the loss of binding of 
the 9znfPLZF-VP16 protein to DNA. This loss of activa-
tion was not noted in the presence of HDAC1 expression, 
or while using the zinc finger point mutants (PLZF-Q), 
and was corrected by TSA treatment in the presence of 
HDAC3 over-expression (Fig. 3b).
Similarly, co-expression of PLZF and SIRT1 relieved 
the PLZF-mediated repression, resulting in only a 25  % 
repression of luciferase activity compared to 70 % repres-
sion with PLZF in the absence of SIRT1 (Fig. 3c.1) asso-
ciated with a decrease of PLZF binding site occupancy 
(Fig.  3c.2). Conversely, inhibition of SIRT1 with the 
sirtuin inhibitor, nicotinamide (NC) [44] significantly 
enhanced PLZF mediated repression (Fig.  3c.1) associ-
ated with a nine-fold enrichment of PLZF binding after 
SIRT1 inhibition (Fig. 3c.2).
HDAC3/SIRT1‑mediated deacetylation inhibits PLZF 
binding activity altering its cellular localization 
and blocking its epigenetic function
The in  vitro results of the reporter experiments con-
taining the PLZF DNA binding sequences were cor-
roborated by a ChIP assay on endogenous targets. We 
transfected PLZF into 293T cells and showed that PLZF 
could interact with previously identified genomic DNA 
targets (Fig. 4a, white bars). PLZF binding activity in vivo 
was decreased by co-transfection of HDAC3 and SIRT1 
expression plasmid but not of an empty vector. The 
results of this analysis closely reflect those of the experi-
ments assaying reporter gene activity (Fig. 3a.2, c.2) and 
those that indicate that PLZF is found acetylated when 
ectopically transfected in cells (Fig.  2). We then exam-
ined, whether the expression of HDAC3 and SIRT1 could 
impaired PLZF nuclear localization status, since we pre-
viously found that acetylation is necessary for PLZF to 
localize in a speckled nuclear pattern [19]. Immunofluo-
rescence and confocal microscopy analyses indicated that 
coexpression of PLZF with HDAC3 or SIRT1 disrupts the 
punctate nuclear localization pattern of PLZF (Fig.  4b), 
resulting in a diffuse nuclear PLZF staining consistent 
with immunoblot results indicating no change in total 
PLZF protein (Fig. 2a.1, a.2). Taken together, these results 
suggest that PLZF cellular localization is directly linked 
to its physical interaction with DNA.
When bound to DNA, PLZF promotes hetero-
chromatin formation by inducing epigenetic modi-
fications including histone deacetylation and DNA 
methylation. Expression of the wild-type PLZF protein 
results in decrease of histone H3 acetylation in the region 
surrounding the PLZF binding sites of PLZF endogenous 
targets (Fig.  5a). However, expression of HDAC3 and 
SIRT1 alone do not alter significantly the level of histone 
H3 acetylation, their coexpression in presence  of PLZF 
augment the levels of acetylated histone H3 indicating 
that deacetylation of PLZF by HDAC3 and SIRT1 directly 
affect PLZF-induced deacetylation at these sites (Fig. 5a). 
We have previously shown that PLZF recruitment can 
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Fig. 2 SIRT1 and HDAC3 deacetylase PLZF protein. Detection of PLZF by Western blotting (a). PLZF is deacetylated by SIRT1 (a.1). Expression 
constructs were transfected as indicated into 293T cells, whole cell lysates were extracted and immunoprecipitated with an antibody to the FLAG‑
tagged PLZF construct. Precipitates were immunoblotted with an antibody to acetylated PLZF species (top panel α‑AcK) or FLAG (bottom panel 
α‑FLAG). HDAC3 deacetylates PLZF (a.2). Expression constructs were transfected as indicated into 293T cells, whole cell lysates were extracted and 
immunoprecipitated with an antibody to the FLAG‑tagged PLZF construct. Precipitates were immunoblotted with an antibody to acetylated PLZF 
species (top panel α‑AcK) or FLAG (bottom panel α‑FLAG). Detection of PLZF signatures by nanoimmunoassay. Electropherograms depicting levels 
of total and acetylated PLZF protein (b). Beta‑2 microglobulin was used as loading control. Monoclonal PLZF antibody detects both acetylated 
(grey arrows) and non‑acetylated (green arrow) forms as treatment by a p300 inhibitor (anacardic acid) induces the reduction of pics marked by grey 
arrows. Histogram plot (c) showing the ratio of acetylated versus non‑acetylated forms of PLZF under the different conditions (PLZF only: PLZF; 
anacardic acid treatment: PLZF + p300i; co‑expression of PLZF and HDAC3: PLZF + HDAC3 and co‑expression of PLZF and SIRT1: PLZF + SIRT1). 
Each reaction was done in triplicate
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tether DNA methyltransferase activities (e.g. DNMT1) to 
specific DNA targets. Thus, PLZF induces DNA hyper-
methylation of CpG islands of the CRABPI gene and of 
the LINE-1 retrotransposon promoters [6, 15]. We per-
formed methyl DNA immunoprecipitation (MeDIP) to 
assess the DNA methylation enrichment at PLZF tar-
get genes in absence or presence of HDAC3 and SIRT1. 
PLZF expression induced CpG hypermethylation of the 
c-myc, CRABPI and LINE-1 promoters, while HDAC3 
and SIRT1 expression alone barely affected DNA methyl-
ation (Fig. 5b). However, co-expression of these deacety-
lases reduced significantly the hypermethylation induced 
by PLZF expression (Fig. 5b). Finally, to further confirm 
the inhibitory effects of HDAC3 and SIRT1 on PLZF 
activity, c-myc, CRABPI and LINE-1 expression was 
measured. Expression of either HDAC3, or SIRT1, was 
associated with an increase in expression of these PLZF 
target genes (Fig.  5c) and correlated with the change of 
epigenetic profiles at these promoters.
Discussion
Post-translational modifications are crucial for regulat-
ing the functions of many eukaryotic proteins and among 
them, lysine acetylation has proven to be important for 
controlling transcription factor activity [45–47]. While 
acetylation of PLZF on lysine residues decisively leads to 
activation [6, 19], little is known about the inverse dea-
cetylation mechanisms. In this study, we demonstrated 
a physical and functional interaction between PLZF and 
two subtypes of deacetylases, the histone Zn+ depend-
ent deacetylase 3, HDAC3, and the NAD+ dependent 
deacetylase sirtuin, SIRT1. Unlike other reported dea-
cetylases interacting with the repression domain of PLZF, 
these proteins interact with a specific domain (ZF 3–9) 
in the zinc finger region of PLZF corresponding to the 
interacting domain with CBP/p300 protein [19] including 
the activating acetylation motif (in ZF9). We have shown 
that these deacetylases effectively deacetylase PLZF 
in vitro and in vivo and that a specific mutant PLZF-Q, 
constitutively acetylated is not regulated by these deacet-
ylases. PLZF-induced deacetylation leads to a decrease of 
its ability to interact interaction with endogenous DNA 
sequences, which in turn affects PLZF nuclear localiza-
tion pattern. Interestingly, PLZF was recently reported to 
be acetylated at lysine 277 by the acetyltransferase HAT1 
[41]. The acetylation at this site is necessary for PLZF to 
form a corepressor complex with HDAC3 and NK-kB in 
order to regulate inflammatory program [40, 41]. In this 
specific setting, PLZF doesn’t interact directly with DNA 
but is recruited to genomic targets through NF-kB inter-
action, indicating that specific PLZF acetylation could 
also affect PLZF function at different levels.
The cellular targets of PLZF play critical roles in cel-
lular senescence c-myc [48], Retinoic acid-induced 
myeloid differentiation (CRABPI, [15]) and in the regu-
lation of retrotransposon [6]. Over-expression of either 
HDAC3 and SIRT1 alter the PLZF-induced epigenetic 
profiles of CpG islands in these PLZF targets, leading to 
a decrease of DNA methylation and an increase in his-
tone acetylation of these loci. Indeed, these promoters 
switch from heterochromatic feature (histone deacety-
lation/DNA methylation) to an euchromatic status 
(See figure on previous page.) 
Fig. 3 HDAC3/SIRT1‑induced deacetylation affect PLZF DNA binding and transcriptional activities. HDAC3 over‑expression influence PLZF activities 
in vivo (a). Transcriptional repression by PLZF is blocked by HDAC3 (a.1). 293T cells were transfected with construct as indicated. Cells were lysated 
at 18 h post transfection and luciferase assays performed. Luciferase activity is expressed relative to the activity in the vector only sample (white 
bars). PLZF alone, light grey bars. HDAC3 alone, black bars. PLZF and HDAC3, dark grey bars, PLZF and HDAC3 with TSA treatment, striped bars and 
PLZF‑Q mutant dotted bars. Each experiment was performed in triplicate and the data represents the average of at least three experiments. Errors 
bars standard error of mean. Lower panel control of PLZF expression using immunoblotting detection with a FLAG antibody (bottom panel α‑FLAG). 
Chromatin immunoprecipitation of the PLZF target (a.2). Flagged PLZF transfected 293T cells were treated with either DMSO or 20 nM Trichostatin 
A, and used for chromatin immunoprecipitation with an antibody against either FLAG or a IgG antibody control. For each condition, the amount of 
the HoxB2 promoter DNA spanning a PLZF binding site bound by each antibody was amplified and quantified by real‑time PCR. This was expressed 
to the signal obtained from the 5 % input chromatin samples. Transcriptional PLZF binding activity is regulated by PLZF acetylation (b). The activ‑
ity of the chimeric protein 9znfPLZF‑VP16 was tested in transient transfection experiments and compare to the Lex‑VP16 chimeric protein. Where 
indicated HDAC1 or HDAC3 expression vectors were cotransfected with increasing amount amount (1, 50 ng; 2, 100 ng, 3, 150 ng). Each experiment 
was performed in triplicate and the data represents the average of at least three experiments. Errors bars standard error of mean. SIRT1 over‑expres‑
sion influence PLZF activities in vivo (c). Transcriptional repression by PLZF is blocked by HDAC3 (c.1). 293T cells were transfected with constructs 
as indicated. Cells were lysed at 18 h post transfection and luciferase assays performed. Luciferase activity is expressed relative to the activity in the 
vector only sample (white bars). PLZF alone, light grey bars. SIRT1 alone, black bars. PLZF and SIRT1, dark grey bars and PLZF and SIRT1 with nicotina‑
mide treatment, striped bars. Luciferase activity is expressed relative to the activity in the vector only sample (white bars). Error bars standard error 
of the mean. 2.5 kb of the c‑myc promoter, −1.8 kb to +0.7 kb relative to the P1 promoter, 5′ to luciferase. Lower panel control of PLZF expression 
using immunoblotting detection with a FLAG antibody (bottom panel α‑FLAG). Chromatin immunoprecipitation of the PLZF target (c.2). Transfected 
cells were treated with either DMSO or 10 mM nicotinamide, and used for chromatin immunoprecipitation with an antibody against PLZF For each 
condition, the amount of c‑myc promoter DNA spanning a PLZF binding site bound by each antibody was amplified and quantified by real‑time 
PCR. This was expressed relative to the signal obtained from the 5 % input chromatin sample
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(histone acetylation/DNA hypomethylation) in the pres-
ence of HDAC3 and SIRT1 deacetylases; ultimately, lead-
ing to de novo expression of PLZF target genes. Here, 
we have described the interplay between PLZF activity 
and HADC3/SIRT1 enzymatic functions, however, the 
characterization of this regulatory mechanism needs to 
be investigated in PLZF target tissues.
PLZF is expressed in hematopoietic stem cells (HSC) 
[4, 5] and generally represses hematopoietic develop-
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loss of PLZF acetylation is associated with a subse-
quent increase or loss of hematopoietic progenitors 
cells, respectively [6]. Loss of HDAC3 expression, which 
would lead to hyperacetylation and activation of PLZF, 
dramatically improves HSC (CD34+) cell expansion 
[49]. Likewise, SIRT1-deficient bone marrow cells con-
fer stable bone marrow reconstitution in competitive 
repopulation and serial transplantation experiments 
[50]. Similarly, PLZF is a key factor involved in the main-
tenance of germinal stem cells [6, 8] and its expression 
is downregulated during spermatogenesis [51]. Recently, 
SIRT1 has also been described as a key factor involved 
in differentiation of male germ cells [52], indicating a 
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Fig. 4 Effect of PLZF deacetylation. PLZF occupancy of its endogenous DNA binding sites (a). Transfected 293T cells were used for chromatin 
immunoprecipitation with an antibody against PLZF or an antibody against histone H3 as positive control. For each condition, the amount of 
LINE‑1, CRABPI and c‑myc DNA spanning a PLZF binding site bound by each antibody was amplified and quantified by real‑time PCR. This was 
expressed relative to the signal obtained from the 5 % input chromatin sample. PLZF localizes in specific subnuclear compartments in the presence 
or absence of HDAC3 and SIRT1 deacetylases (b). The nuclear localization pattern of PLZF (and indicated conditions) was analyzed in 293T cells 
transfected with PLZF alone (PLZF) or in the presence of HDAC3 (PLZF + HDAC3) and SIRT1 (PLZF + SIRT1), by indirect immunofluorescence and 
confocal microscopy, as reported previously [19], punctate nuclear distribution of wild‑type PLZF was observed (PLZF). Only diffuse nuclear localiza‑
tion was observed when PLZF was co‑expressed with HDAC3 (PLZF + HDAC3), whereas co‑expression of PLZF and SIRT1 (PLZF + SIRT1) show 
both diffuse and punctate localization (at a lesser degree than PLZF alone). No immunofluorescence signal was observed when primary anti‑PLZF 
monoclonal antibody was omitted from the experimental procedure

























































































PLZF + HDAC3 

























PLZF + HDAC3 
PLZF + SIRT1 
c-myc CRABPI 
Fig. 5 PLZF epigenetic effects on its endogenous targets and their related gene expression. Histone H3 enrichment at PLZF promoter targets (a). 
Transfected 293T cells were used for chromatin immunoprecipitation with an antibody against histone H3 or an antibody against acetylated forms 
of histone H3. For each condition, the amount of LINE‑1, CRABPI and c‑myc promoters bound by each antibody was amplified and quantified by 
real‑time PCR. This was expressed relative to the signal obtained from the 5 % input chromatin sample and corrected by the signal obtained with 
the total histone H3 immunoprecipitation. DNA methylation enrichment of CpG promoters (b). MeDIP assay of the LINE‑1, c‑myc, CRABPI and H19 
promoter regions in the PLZF with or without HDAC3 or SIRT1 expression cells. Cells were harvested 24 h after transfection and genomic DNA for 
MeDIP analysis with specific 5 mC antibody was isolated. Immunoprecipitated DNA was amplified by gene specific quantitative PCR. To quantify the 
amount of DNA methylation in these regions, the ratio of ΔCT of the MeDIP and input samples are calculated by comparing MeDIP samples against 
input (sonicated library DNA was set aside before MeDIP was performed for use as input DNA). The data are normalized to the DNA methylation 
at the UBE locus and fold enrichment ratio calculated in comparison to the untransfected cells. A representative dataset from these experiments, 
which were repeated 3 times, is shown. H19 locus was used as control of DNA methylation (known to be methylated in human) and as a non‑
PLZF targeted promoter. White bars represent transfection with the empty vector and the black bar with PLZF expression vector in presence (+) or 
absence (−) of HDAC3 or SIRT1 co‑transfection. Relative gene expression of endogenous PLZF targets (c). To measure expression of PLZF targets, 
mRNA expression was measured at 12 h post‑transfection in 293T cells using SYBR green quantitative real‑time PCR. After normalization to GAPDH, 
expression levels of LINE‑1, c‑myc and CRABPI genes are presented as mean ± standard deviation. The experiments were conducted in triplicate
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in order to regulate maintenance and differentiation of 
these cells.
To date, SIRT1 and HDAC3 appear to be complex 
regulatory factors with multiple roles in cell biology and 
transcriptional regulation and have been suggested as 
anti-cancers targets. HDAC3 is involved in the regulation 
of cancer-associated cellular process like apoptosis, and 
is also important in the regulation of cancer-associated 
transcription factors functions, including PCAF, SRY, 
NF-kB and STAT proteins [53]. SIRT1 deacetylates a 
growing list of non-histone proteins including transcrip-
tional factors p53, NF-kB, nuclear receptors and c-myc 
[29, 30]. Here, we have shown that SIRT1 and HDAC3 
bind to PLZF and negatively regulate its transcriptional 
activity suggesting a pivotal role in key cell function 
through PLZF [11]. Abnormal overexpression of these 
deacetylases could lead to the inhibition of PLZF repres-
sion and lead to proliferative advantage by up-regulation 
of c-myc, or increased genomic instability by reactivation 
of LINE-1 retrotransposons, both mechanisms shown to 
be involved in oncogenesis [54, 55]. This functional inhi-
bition of PLZF is correlated with abnormal cytoplasmic 
localization and a recent study shows that high cytoplas-
mic detection of PLZF might be correlated with metasta-
sis in thyroid carcinomas [56].
Conclusions
Here we show that the acetylation site located in the 
zinc finger region of PLZF is a substrate of HDAC3 and 
SIRT1 deacetylases. When acetylated, PLZF binds to its 
DNA binding sites, and induces histone deacetylation 
and DNA hypermethylation followed by PLZF target 
genes repression. Specific deacetylation of PLZF by these 
deacetylases induces a loss of PLZF binding to its target 
genes, associated with epigenetic changes (e.g. histone 
acetylation and DNA hypomethylation) and ultimately 
leading to PLZF target genes expression. In conclusion, 
all the factors controlling both acetylation and deacetyla-
tion of PLZF are not well known, or are their effects well 
characterized, but their interplay will be critical for main-
taining the balance of PLZF functions in cell differentia-
tion and stem cell biology.
Methods
Protein affinity chromatography
Equivalent amounts of GST, GST-PLZF, or the various 
PLZF deletion constructs, each on beads, were incubated 
in 25  mM HEPES pH 7.5, 12.5  mM MgCl2, 150  mM 
NaCl, 20  % glycerol, 0.1  % NP40, 1  mM DTT, 20  μM 
ZnCl2, 3 µg BSA for 10 min at room temperature, before 
addition of recombinant His-SIRT1 for 1 h at room tem-
perature. Beads were then washed 4× in 20 mM Tris pH 
8.0, 100  mM NaCl, 1  mM EDTA, 0.5  % NP40. Samples 
were analyzed by SDS-PAGE followed by western blot-
ting with anti-His antibody (Santa Cruz) and Ponceau 
staining of the membrane.
In vitro immunoprecipitation
[35S]methionine-labeled proteins were synthesized 
in  vitro using the TNT coupled transcription-transla-
tion system (Promega), following the supplier’s direc-
tions. Assays were performed in NETN buffer (20  mM 
Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 % NP40) at 
4  °C for 60 min with gentle rocking. Immunocomplexes 
were isolated by further incubation with an appropriate 
antibody preadsorbed on protein A/G-Sepharose (Phar-
macia), washed five times in H buffer (20  mM HEPES, 
pH 7.7, 50 mM KCl, 20 % glycerol, 0.1 % NP40). Bound 
proteins were eluted in Laemmli loading buffer and sepa-
rated on a 5 or 10 % SDS-PAGE. Gels were fixed in 25 % 
isopropanol and 10 % acetic acid, dried, and exposed to 
Kodak Biomax film. Anti-p300 (Santa Cruz Biotechnol-
ogy), anti-Gal4 (Santa Cruz Biotechnology), rabbit poly-
clonal anti-acetyl-lysine (Upstate Biotechnology, catalog 
no. 06-933), and anti-Flag (Sigma) antibodies were pur-
chased from the indicated suppliers and used as directed.
Cell culture and transfection
KG1a cells were maintained in IMDM supplemented 
with 10 % heat-inactivated fetal bovine serum. For trans-
fection of KG1a cells, 2 × 107 cells per transfection were 
washed once in IMDM with no additives, resuspended in 
400 μL of additive-free media and mixed with 20 μg of 
DNA in a 4 mm gap cuvette. Electroporation was carried 
out at 72 W, 220 V and 2800 μF in a BTX 600 electropo-
rator (Genetronics, San Diego, CA, USA), the cells were 
allowed to recover at room temperature for 10 min, then 
plated into maintenance media. 293T cells were main-
tained in DMEM with 10 % heat-inactivated fetal bovine 
serum. 293T cells were plated 16  h before transfection 
with Superfect (Qiagen, Valencia, CA, USA). For every 
1 microgram of plasmid DNA, 5  μL of Superfect was 
mixed with 90  μL of additive-free DMEM (Invitrogen, 
Carlsbad, CA, USA) and incubated at room temperature 
for 15  min. One mL of maintenance media was added 
and the DNA/Superfect/media mix was overlaid onto 
freshly washed 293T cells. This mix was removed after 
3 h and replaced with maintenance media.
Immunofluorescence and confocal microscopy
For immunofluorescence, cells were fixed in 4  % para-
formaldehyde for 20  min at room temperature. Slides 
were then washed twice for 5  min in Ca2+- and Mg2+-
free phosphate buffered saline (PBS) solution and cyto-
spin onto polylysine-coated slides and permeabilized 
with 0.3 % Triton in PBS for 5 min at room temperature, 
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washed twice for 5 min in PBS, and incubated in block-
ing buffer (1 % bovine serum albumin in PBS) for 30 min 
at room temperature. Cells were then incubated with 
mouse monoclonal anti-PLZF antibody (diluted 1:500 in 
blocking buffer) for 2  h at room temperature, followed 
by three 5-min washes in PBS. Secondary fluorescein 
isothiocyanate (FITC)-conjugated anti-mouse antibody 
(diluted 1:200 in blocking buffer) (Jackson ImmunoRe-
search Laboratories) was then applied for 2 h. Cells were 
subsequently washed twice for 5  min in PBS and then 
twice for 5  min in PBS plus To-pro3 iodide (dilution, 
1:10,000). Cells were mounted in Vectashield mounting 
medium, sealed with nail varnish, and visualized using 
the Leica TCS SP2 true confocal system.
Reporter assays
The luciferase reporter, PLZF and Sirt1 or HDAC3 
expression plasmids were used in a 5:4:3 ratio respec-
tively, with 10  ng of renilla luciferase included as an 
internal control for every microgram of plasmid DNA. 
293T cells were transfected as described above. Trans-
fected cells were harvested at 42–45 h post-transfection 
and lysates assayed for luciferase activity using the Dual 
Luciferase kit (Promega, Madison, WI, USA) as recom-
mended by the manufacturer. Raw values obtained for 
each experimental point, performed in triplicate, were 
normalized to the renilla value for each replicate. The 
error for each experiment is represented by standard 
error of the mean for each triplicate. Data presented is 
from a representative experiment, the same effect was 
observed in at least three independent experiments.
Quantitative RT‑PCR
RNA was extracted from 0.5 × 105 to 1 × 107 cells using 
the RNeasy protocol, as recommended by the manufac-
turer (RNeasy, Qiagen, Valencia CA, USA), and cDNA 
produced using a mixture of random hexamers and oligo 
dT priming (iScript reverse transcriptase, Biorad, Hercules, 
CA, USA). Quantitative PCR was carried out in triplicate 
using the Quantitect SYBR Green master mix kit (Qiagen, 
Valencia, CA, USA) according to the manufacturers rec-
ommendations, in an Opticon DNA Engine (MJ Research, 










The cycle threshold (Ct) value for the ‘DMSO’ sample 
was taken as baseline expression, and ΔCt, the difference 
between the DMSO Ct and the Ct obtained after treat-
ment, was calculated for each PCR. The ΔCt for each 
transcript was expressed relative to the ΔCt for GAPDH 
in each experiment. The formula 2ΔCt was used to cal-
culate the fold change in gene expression after nicotina-
mide treatment. Efficiency of amplification was shown to 
be equivalent for all primers.
Immunoprecipitation
For endogenous co-immunoprecipitation, whole cell 
lysates were prepared from 2 × 108 KG1a cells using 1 % 
NP40, 150  mM NaCl, 20  mM Tris pH 8.0 with a pro-
tease inhibitor cocktail (Complete, Roche, Indianapolis, 
IN, USA). Ten percent of each sample was reserved, and 
the remainder of the lysate was precleared by incubation 
with protein A agarose for 1 h at 4 °C. After centrifuga-
tion, the cleared lysate was divided up and incubated 
with 2  µg of either PLZF monoclonal antibody (EMD 
Biosciences, San Diego, CA, USA), HDAC3 monoclonal 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) or anti-SIRT1 polyclonal antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) as necessary for 16 h 
at 4 °C. Immune complexes were collected by incubation 
with 20  μL of protein A agarose for 1  h, washed three 
times in whole cell lysate buffer, and denatured by boiling 
in 40 μL of SDS loading buffer. For immunoprecipitation 
from nuclear extracts, the soluble nuclear fraction was 
obtained as previously described [19]. For anti-acetyl-
lysine immunoprecipitations, each 10  cm plate of 293T 
cells was resuspended in 50  μL ice-cold PBS, 50  μL of 
2  % SDS/PBS was added, and the lysates incubated at 
95 °C for 10 min. The volume was taken to 1 mL with 1 % 
NP40, 150 mM NaCl, 20 mM Tris pH8 with a protease 
inhibitor cocktail (Complete, Roche, Indianapolis, IA, 
USA) and incubated 30  min on ice. Insoluble material 
was pelleted by centrifugation at 13,000 rpm for 15 min, 
and the supernatant retained for immunoprecipitation, 
which was carried out as described above with 1 μg of 
anti-acetyl lysine antibody (Merck Millipore) per sample.
Chromatin and methyl DNA immunoprecipitation
Antibodies used were against PLZF (EMD Biosciences, 
San Diego, CA, USA), FLAG M2 (Sigma, St Louis, MO, 
USA), histone H3, pan-acetyl histone H3 and 5-methyl-
cytosine (Abcam). For each immunoprecipitation, 293T 
cells were seeded at 1 × 105/mL transfected and treated 
with either 10  mM nicotinamide, 10  mM of Trichos-
tatin A or the appropriate volume of DMSO vehicle 
control for 18  h. Cells were then fixed in 1  % formal-
dehyde at room temperature for 30  min with shaking 
and quenched in 0.125  M glycine for 5  min at room 
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temperature. Cells were washed twice in PBS contain-
ing complete protease inhibitor (Roche, Indianapo-
lis, IN, USA) and lysed in 1.0 mL lysis buffer (140 mM 
NaCl, 10  mM Tris pH8, 1  % NP40) per 1  ×  107 cells. 
Lysates were sonicated to break DNA into fragments 
less than 1 kb (Dismembrator, Diagenode, Philadelphia, 
PA, USA), and pre-cleared for 45–60 min with protein 
A agarose beads with 0.4  μg/μL salmon sperm DNA 
(Upstate, Charlottesville, VA, USA). After brief cen-
trifugation, supernatant was removed and incubated 
with 5  μg of the precipitating antibody overnight at 
4 °C. Protein A/salmon sperm DNA was added, and the 
immune complex collected for 1  h at 4  °C. Complexes 
were washed for 5  min each in low salt buffer (0.1  % 
SDS, 1 % Triton-x100, 2 mM EDTA, 20 mM Tris–HCl 
pH 8.1, 150 mM NaCl), high salt buffer (0.1 % SDS, 1 % 
Triton-x100, 2  mM EDTA, 20  mM Tris–HCl pH 8.1, 
500 mM NaCl), LiCl buffer (0.25 M LiCl, 1 % NP40, 1 % 
sodium deoxycholate, 1  mM EDTA, 10  mM Tris–HCl, 
pH 8.1), then washed twice in TE. DNA was eluted for 
2 × 15 min in 250 μL 1 % SDS, 0.1 M NaHCO3, and the 
two eluates combined. 20  μL of 5  M NaCl was added 
and eluates incubated at 65 °C overnight to reverse the 
cross-links. DNA was recovered by phenol–chloroform 
extraction and ethanol precipitation, then used in a 
PCR reaction. The primer sequences used for PCR were:
UBE2B promoter F: 5′-CTCAGGGGTGGATTGTTG 
AC-3′
UBE2B promoter R: 5′-TGTGGATTCAAAGACCAC 
GA-3′
H19 ICR F: 5′-GAGCCGCACCAGATCTTCAG-3′
H19 ICR R: 5′-TTGGTGGAACACACTGTGATCA-3′
c-myc promoter F: 5′-AATGCCTTTGGGTGAGGG 
AC-3′
c-myc promoter R: 5′-TCCGTGCCTTTTTTTGGGG-3′
Line-1 PLZF-BS F: 5′-GAACTCTCCACCCCAAAT 
CA-3′
Line-1 PLZF-BS R: 5′-CCATGTAGTTGAGCGGCT 
TT-3′
CrabpI PLZF-BS F: 5′-AGTCTCTATATAACAAGAG 
GCA-3′
CrabpI PLZF-BS R: 5′-TCAGAACCATGTTAATTT 
TCCA-3′
Line-1 CpG F: 5′-CGAATATTGCGCTTTTCAGA-3′
Line-1 CpG R: 5′-CCGGCTGCTTTGTTTACCTA-3′
CrabpI CpG F: 5′-ATTTCGACGAGCTGCTCA 
AG-3′
CrabpI CpG R: 5′-CTACCAGCTTCTCCGAGACC-3′
Luciferase reporter F: 5′-GGATCCCCACTTAAC 
ACCCAA-3′
Luciferase reporter R: 5′-CTTGGGAAACTGCTCT-
TAACTAG-3′ (described in [15, 19]).
Immunoblot analysis
Proteins were separated by 10  % SDS–polyacrylamide 
gel electrophoresis, and transferred to PVDF membrane 
(Millipore, Bedford, MA, USA) in a 25 mM Tris, 192 mM 
glycine buffer. The membrane was blocked in PBS/5  % 
skim milk powder overnight. Incubation of the mem-
brane with the primary antibody was carried out at room 
temperature for 1 h in PBS/0.5 % skim milk, membranes 
were washed three times for 5 min in PBS, and the appro-
priate HRP-conjugated secondary antibody added to PBS 
at the concentration recommended by the manufacturer 
(Chemicon, Temecula, CA, USA). The HRP conjugate 
was detected by chemiluminescence using the ECL kit 
(Amersham, Piscataway, NJ, USA) and autofluorography. 
Antibodies used were against PLZF (EMD Biosciences, 
San Diego, CA, USA), SIRT1 (Santa Cruz Biotechnology), 
HDAC3 (Santa Cruz Biotechnology), the myc epitope tag 
(Santa Cruz Biotechnology), and GAPDH (Chemicon).
Nanofluidic detection
The NanoPro 1000 system (ProteinSimple) is built on 
an automated, capillary-based immunoassay platform 
and enables a rapid and quantitative analysis of specific 
proteins and their post-translational modification states. 
We have utilized this nano-immunoassay to examine 
the acetylation profiles of the PLZF protein. All isoelec-
tric separations were performed on the NanoPro 1000 
(ProteinSimple, Santa Clara, CA, USA) with the Premix 
Generation 2 pH 3–10 separation mix (Cat #040–968). 
Standard pI Ladder 1 (ProteinSimple Cat #040–644) was 
added to the ampholyte pre-mix. Lysates were then sepa-
rated for 40 min at 21,000 μW in individual capillaries. 
After separation the proteins in the lysate were immobi-
lized to the capillary wall by subjecting them to UV expo-
sure for a period of 80 s. After two washes of 150 s each, 
primary antibodies were introduced into the capillaries 
for a period of 2 h. Antibody for PLZF were used at a 1:75 
dilution, whereas antibody for β-2 microglobulin were 
used at 1:100 dilutions. After another two washes of 150 s 
each, samples were run either with or without amplifica-
tion reagents. Secondary anti-rabbit-HRP-conjugated 
antibodies (ProteinSimple Cat #040–656) or second-
ary anti-mouse-biotin-conjugated antibodies (Protein-
Simple’s amplified mouse secondary antibody kit—Cat 
#041–127) were loaded into the capillary for 1 h. Ampli-
fication was performed only for PLZF antibody. After a 
third set of two washes of 150 s each, either streptavidin, 
conjugated with horse radish peroxidase (ProteinSim-
ple Cat #041–126), or antibody diluent was loaded into 
the capillary for 2 h or 10 min respectively. After a final 
two wash cycle of 150  s each, a luminol-peroxidase 1:1 
mix (ProteinSimple Cat #040–0652 and 040–684) was 
flowed through the capillaries and chemiluminescence 
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was detected at 30, 60, 120, 240, 480, and 960 s. Primary 
monoclonal PLZF antibody (Abcam Ab104854) was used 
for the assay. To determine acetylation-peaks, sample 
lysates were treated with anacardic acid (AA) for 12  h 
(20 mM, Sigma SMB00129).
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